Lab-Grown ‘Mini Brains’ May Predict Which Alzheimer’s Patients Respond to Antidepressants
Lab-grown clusters of human brain tissue may help predict which people with Alzheimer’s disease respond to commonly prescribed antidepressants, according to new research from Johns Hopkins Medicine. The experimental models, known as brain organoids, were grown from patients’ own cells and reproduced key molecular features of the disease.
The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, suggests these mini brains could one day help guide more personalized treatment for the neuropsychiatric symptoms that affect nearly all Alzheimer’s patients. These symptoms include anxiety, depression and agitation.
How mini brains are created
Researchers began with blood samples from volunteers with Alzheimer’s disease and healthy individuals enrolled through the Johns Hopkins Alzheimer’s Disease Research Center. Blood cells were reprogrammed into induced pluripotent stem cells, which have the ability to develop into many different tissue types.
Using these stem cells, the team generated hindbrain organoids, small pea-sized structures that mimic a brain region involved in regulating breathing, sleep and heart rate. The organoids included neurons that produce serotonin, a key neurotransmitter targeted by many antidepressants.
The project involved hundreds of organoids representing individual patients, which the authors say makes it one of the largest organoid-based Alzheimer’s studies to date. This scale allowed researchers to compare molecular responses across a wide range of patient-derived samples.
Distinct Alzheimer’s-like changes observed
Organoids grown from the cells of Alzheimer’s patients showed clear molecular differences from those derived from healthy donors. The Alzheimer’s models displayed alterations in proteins associated with cell-to-cell communication, inflammation and known disease pathways.
These changes indicate that the mini brains can reproduce important aspects of Alzheimer’s biology despite being simplified systems grown in the laboratory. That similarity is critical if organoids are eventually to be used to test potential treatments or predict real-world responses to medications.
The researchers then exposed the organoids to escitalopram oxalate, a widely used selective serotonin reuptake inhibitor that is often prescribed off-label for Alzheimer’s-related behavioral symptoms. Responses to the medication varied significantly among different patient-derived organoids.
Antidepressant response varies by organoid
In some Alzheimer’s organoids, escitalopram increased proteins involved in serotonin signaling and synaptic communication, aligning with how SSRIs are expected to work in the brain. In others, the same treatment produced little or no measurable molecular change.
This divergence suggests that patient-specific biology strongly influences how brain tissue responds to antidepressants. If the findings are validated in clinical studies, organoids could potentially help identify which patients are more likely to benefit from particular medications.
Lead author Vasiliki Machairaki says large-scale, patient-derived organoids may eventually support the staging of Alzheimer’s disease, investigation of disease mechanisms and selection of targeted therapies for defined subgroups of patients.
Extracellular vesicles as potential biomarkers
The researchers also examined tiny membrane-bound particles called extracellular vesicles that were released by the organoids. These vesicles carry proteins and other molecules reflecting the state of their parent cells and can be detected in the surrounding fluid.
Analysis revealed that vesicles from Alzheimer’s organoids contained altered levels of several disease-associated proteins, including RAB3A, NSF and ATCAY, which are important for normal neuronal signaling. Levels of these proteins were lower compared with vesicles from healthy control organoids.
After treatment with escitalopram, some organoids showed increased amounts of proteins associated with serotonin signaling and synaptic pathways within their vesicles. Other samples showed minimal changes, again reflecting the variable drug responses observed within the organoids themselves.
Toward liquid biopsy-style brain tests
The team believes that extracellular vesicles could eventually function as biomarkers to help diagnose Alzheimer’s disease, determine disease stage and even predict treatment response. Such biomarkers could provide the basis for future liquid biopsy-style tests for brain disorders.
In the long term, Machairaki aims to develop more complex organoids that incorporate immune cells and vessel-like networks to more closely mimic human brain tissue. These advances could improve how faithfully organoids reproduce the interactions that influence Alzheimer’s progression.
The authors emphasize that the research remains at an early, preclinical stage and that no organoid-based test is currently ready for patient care. Still, the findings support brain organoids as a potentially powerful platform for precision medicine research in neurodegenerative disease.
The study was supported by multiple grants from the U.S. National Institutes of Health, the Paul G. Allen Frontiers Foundation and the Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease at Johns Hopkins University. The authors reported no relevant conflicts of interest under university policies.
